





































































Differential effects of variations in human P450 oxidoreductase on the 
aromatase activity of CYP19A1 polymorphisms R264C and R264H  
 
Shaheena Parween1,2, Giovanna DiNardo3 , Francesca Baj1,2,3, Chao Zhang3, Gianfranco Gilardi3,*, 
and Amit V. Pandey1,2* 
 
1Pediatric Endocrinology, Diabetology, and Metabolism, Department of Pediatrics, University Children’s Hospital Bern, 3010, 
Bern, Switzerland. 2Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland. 
3Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, Torino, Italy 
 
* Correspondence:  
PD Dr. Amit V Pandey: Pediatric Endocrinology, Diabetology & Metabolism, KIKL C837, University Children’s 
Hospital Bern, Freiburgstrasse 15, 3010 Bern Switzerland 
Tel:  +41 31 632 9637  Email: amit@pandeylab.org 
 
Prof. Gianfranco Gilardi: Department of Life Sciences and Systems Biology, University of Torino,  
Via Accademia Albertina 13, Torino, Italy. Tel: +39 011 670 4593 Email: gianfranco.gilardi@unito.it 
 
Abstract: Aromatase (CYP19A1) converts androgens into estrogens and is required for female sexual development and 
growth and development in both sexes. CYP19A1 is a member of cytochrome P450 family of heme-thiolate 
monooxygenases located in the endoplasmic reticulum and depends on reducing equivalents from the reduced 
nicotinamide adenine dinucleotide phosphate via the cytochrome P450 oxidoreductase coded by POR. Both the 
CYP19A1 and POR genes are highly polymorphic, and mutations in both these genes are linked to disorders of steroid 
biosynthesis. We have previously shown that R264C and R264H mutations in CYP19A1, as well as mutations in POR, 
result in a reduction of CYP19A1 activity. The R264C is a common polymorphic variant of CYP19A1, with high 
frequency in Asian and African populations. Polymorphic alleles of POR are found in all populations studied so far and, 
therefore, may influence activities of CYP19A1 allelic variants. So far, effects of variations in POR on enzymatic 
activities of allelic variants of CYP19A1 or any other steroid metabolizing cytochrome P450 proteins have not been 
studied. Here we are reporting the effects of three POR variants on the aromatase activities of two CYP19A1 variants, 
R264C and R264H.  We used bacterially expressed and purified preparations of WT and variant forms of CYP19A1 and 
POR and constructed liposomes with embedded CYP19A1 and POR proteins and assayed the CYP19A1 activities using 
radiolabeled androstenedione as a substrate.  With the WT-POR as a redox partner, the R264C-CYP19A1 showed only 
15% of aromatase activity, but the R264H had 87% of aromatase activity compared to WT-CYP19A1. With P284L-
POR as a redox partner, R264C-CYP19A1 lost all activity but retained 6.7% of activity when P284T-POR was used as 
a redox partner. The R264H-CYP19A1 showed low activities with both the POR-P284L as well as the POR-P284T. 
When the POR-Y607C was used as a redox partner, the R264C-CYP19A1 retained around 5% of CYP19A1 activity. 
Remarkably, The R264H-CYP19A1 had more than three-fold higher activity compared to WT-CYP19A1 when the 
POR-Y607C was used as the redox partner, pointing towards a beneficial effect. The slight increase in activity of R264C-
CYP19A1 with the P284T-POR and the three-fold increase in activity of the R264H-CYP19A1 with the Y607C-POR 
point towards a conformational effect and role of protein-protein interaction governed by the R264C and R264H 
substitutions in the CYP19A1 as well as P284L, P284T and Y607C variants of POR. These studies demonstrate that the 
allelic variants of P450 when present with a variant form of POR may show different activities, and combined effects of 
variations in both the P450 enzymes as well as in the POR should be considered when genetic data are available. Recent 
trends in the whole-exome and whole-genome sequencing as diagnostic tools will permit combined evaluation of 
variations in multiple genes that are interdependent and may guide treatment options by adjusting therapeutic 
interventions based on laboratory analysis. 
Keywords: CYP19A1; Aromatase; P450 oxidoreductase; estrogen synthase;POR; cytochrome P450. 
 
1 Introduction 
Aromatase (CYP19A1, EC: 1.14.14.14) regulates estrogen biosynthesis [1] by converting androgens into 
estrogens [2, 3]. CYP19A1 is a 503 amino acid protein (NP_000094) encoded by the CYP19A1 gene 
(GeneID:1588, NCBI: NM_000103), located on chromosome 15 (15q21.2, GRCh38 15:51208056-51338597). 




cytochrome P450 superfamily. Cytochrome P450 enzymes are involved in the biosynthesis of steroid 
hormones, and they also metabolize drugs and xenobiotics [4]. Two different types of the cytochrome P450 
family of proteins are present in humans [5]. The P450 type 1 proteins are found in the mitochondrion and are 
responsible for the metabolism of steroid hormones and sterols and are targets for drugs in a range of disorders 
[6-11]. The P450 type 2 proteins are localized in the endoplasmic reticulum and have a range of metabolic 
activities, including drugs, xenobiotics as well as endogenous substrates, and steroid hormones like 
progesterone, dehydroepiandrosterone, and testosterone [12-17]. Genetic defects in steroid metabolizing 
cytochromes P450 and their redox partners cause metabolic disorders with disordered steroidogenesis [18-25]. 
CYP19A1 is highly expressed in ovaries and plays a significant role in the regulation of the reproductive cycle 
in females [26]. In males, CYP19A1 is expressed in the gonads, and the paracrine effects of CYP19A1 reaction 
products are required for normal spermatogenesis [27-30]. 
Additionally, CYP19A1 expression is also found in extra-gonadal tissues, including liver, muscle, 
placenta, bone, breast, adipose tissue, and brain [26, 31, 32]. Initial work on the characterization of CYP19A1 
was done on enzyme preparations purified from the placenta by laboratories of Hall [33], Vickery [34], and 
Harada [35] and a placental protein preparation was also used for the determination of X-ray crystal structure 
of CYP19A1 protein by Ghosh [36]. The CYP19A1 protein is required for the biosynthesis of estrogens (C18 
steroids) from the androgen precursors (C19 steroids) [1, 37]. Some of the critical reactions catalyzed by 
CYP19A1 include the biosynthesis of estrone (E1) from androstenedione, estriol (E3) from 16-
hydroxytestosterone and 17β-estradiol (E2) from testosterone (Figure 1)  [1]. The androstenedione and 
testosterone are well known as the most common physiological steroid substrates for CYP19A1 [1, 38, 39]. 
Recently 16β-OH-androstenedione was also reported to be a substrate for CYP19A1 [40]. The catalytic process 
of aromatization of androgens is multifaceted, and it comprises of three enzymatic reaction steps involving the 
transfer of three pairs of electrons from the co-factor reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) and consumption of oxygen. Electron transfer from NADPH to CYP19A1 is carried out by NADPH 
cytochrome P450 oxidoreductase (POR) [41, 42]. The initial two steps of aromatase reaction are two sequential 
hydroxylation reactions at the 19-methyl group of androgens, whereas the last step causes the aromatization 
of the A-ring of the steroid, which is specific for CYP19A1 [43-45]. 
Multiple genetic defects are associated with the reduced CYP19A1 activity in humans (OMIM: 107910, 
613546, 139300) [19, 46]. In females, a reduction in CYP19A1 activity causes abnormal external genitalia in 
the female fetus, maternal virilization during gestation, healthy development of ovaries but the increased 
occurrence of polycystic ovary syndrome, and virilization at puberty [31, 38]. The first case of CYP19A1 
deficiency in humans was described by Shozu et al. [2]. Later Morishima et al. described that CYP19A1 
deficiency occurs during fetal life in both males and females [47]. Effect of CYP19A1 deficiency on the 
maturation of skeleton, growth, and bone homeostasis [27, 48], as well as abnormal plasma lipid profile and 
variations in insulin resistance, have been reported in multiple publications [19, 30, 31, 38, 49-52]. Estrogen 
excess has also been shown in many publications to cause an increase in the expression and activity of 
CYP19A1 [53, 54]. Several natural compounds, including nicotine, vitamin E, resveratrol and curcumin, may 
inhibit CYP19A1 activity [8, 55, 56]. CYP19A1 activity is also inhibited by bisphenol A and sildenafil [55]. 
CYP19A1 inhibitors like anastrozole are used in the treatment of breast cancer and to treat the excess 
production of estrogen in men [57].  
POR deficiency (PORD, OMIM: 613537 and 201750), is a rare form of congenital adrenal hyperplasia, 
that was first reported in patients with disordered steroidogenesis [24], and later on, multiple disorders have 
been linked to mutations in POR [42, 58-61]. While many cytochromes P450 have been tested with different 
POR variants, allelic variants of the steroid metabolizing cytochromes P450 have not been studied for the 
potential changes in enzyme activities caused by variant forms of POR [42, 60, 62]. Subramanian et al. had 
examined the combined effect of P450 and POR variations in a report describing activities of three common 
alleles of CYP2C9 assayed with the WT and variant forms of POR [63].  Since POR is obligate electron donor 
for all cytochrome P450 proteins in the endoplasmic reticulum, variations in POR should also be taken into 




may severely affect the production of estrogens, and several variations of POR exist with significant population 
distribution, which can alter enzymatic activities of CYP19A1 [64-68]. We, therefore, tested the impact of 
some population variants of POR on estrogen formation by the two variants of CYP19A1. The R264C 
(rs700519) is a common polymorphic variant of CYP19A1(CYP19A1*4) while the R264H (rs2304462) is a 
rare variant. We generated the WT and variant forms of human POR and CYP19A1 in bacteria and used lipid-
based reconstitution to do the enzymatic analysis of CYP19A1-aromatase activity using androstenedione as a 
substrate. We also studied the effect of CYP19A1 variations on protein stability by limited proteolysis to 
understand the potential causes of the changes in enzyme activities by different variants. This study shows that 
variations in POR may have variable effects on activities of CYP19A1 variants, potentially leading to altered 
steroid metabolism in individuals with variant CYP19A1 alleles.
 
 
Figure 1: Steroid hormone biosynthesis and role of POR. A: In the human placenta, DHEA (CHEBI:28689) is 
metabolized to form androstenedione.  Androstenedione then serves as a substrate for the formation of testosterone 
(CHEBI:17347) which is then converted into estrogens. In the liver of the fetus, DHEAS (CHEBI:16814) is 
metabolized into 16αDHEAS (CHEBI:87774), which then gets converted into 16αDHEA inside the placenta to form 
estriol (CHEBI:27978). The biosynthesis of estrogens requires the aromatase activity of CYP19A1, which is reliant 
on POR. Figure adapted from our previous publication by Udhane et al. 2017 [64]. B: Electron transfer from NADPH 
to CYP19A1 is carried out via POR through reduced FAD and FMN. Chemical structures were obtained from ChEBI 
(https://www.ebi.ac.uk/chebi/).
 
2 Materials and methods 
 
Materials: Tris-base, NADPH, acetic acid, 
magnesium acetate, Sucrose, potassium phosphate 
EDTA, DTT, glycerol, PMSF, and Benzonase were 
purchased from Sigma-Aldrich Chemie GmbH 
(Buchs, Switzerland). Carbenicillin, FeCl3, ZnCl2, 
CoCl2, Na2MoO4, CaCl2, CuCl2, M H3BO3 were 
purchased from CarlRoth GmBH (Switzerland).  
Goat anti-rabbit antibodies labeled with infra-red 
dyes were from LI-COR Bioscience Inc. (NE, USA). 
The protein assay dye reagent (RC-DC assay) was 
from Bio-Rad (Hercules, CA). The anti-POR 
antibody was from Genscript (NJ, USA). 
 
Recombinant expression and purification of 
CYP19A1 and its polymorphic variants R264H 




a well-characterized recombinant soluble human 
CYP19A1, which has the structure and activity 
comparable to full-length CYP19A1 [69]. The 
polymorphic variants R264H and R264C of 
CYP19A1 were generated as described previously 
by Baravalle et al. in 2017 [70]. The WT CYP19A1 
and the two polymorphic variants, R264H  and 
R264C, were expressed and purified based on 
previously described methods [69, 71-73]. Briefly, 
the E. coli DH5α rubidium-competent cells were 
transformed with a pCWOri+ plasmid vector 
carrying the CYP19A1 gene and selected with 100 
μg/mL ampicillin. The CYP19A1 protein 
expression was induced by the addition of 1 mM 
Isopropyl β-D-1-thiogalactopyranoside. Liquid 
cultures were grown in the Terrific Broth medium 
in the presence of the heme precursor δ-
aminolevulinic acid at 28°C for 48 hours. Bacterial 
cells were collected and re-suspended in 100 mM 
potassium phosphate (pH 7.4) containing 20 % 
glycerol, 1 % Tween-20, and 1 mM β-
mercaptoethanol supplemented with 1 mg/mL 
lysozyme and a protease inhibitor cocktail (Roche, 
Switzerland) at 4°C. Bacteria were broken by 
sonication and ultra-centrifuged at 100000 x g for 
20 minutes. The cellular supernatant containing the 
soluble proteins was loaded on an ion-exchange 
column (DEAE-Sepharose Fast-Flow, GE 
Healthcare), followed by processing over a Nickel-
ion Chelating-Sepharose Fast-Flow affinity column 
(GE Healthcare). The CYP19A1 protein was eluted 
from the Nickel-Sepharose column with a gradient 
of 1 mM to 40 mM histidine, which was later 
removed by ultrafiltration on the 30 kD molecular 
weight cut-off Amicon concentrator device (Merck-
Millipore).  
  
POR expression and membrane purification: 
The WT POR and variants were produced in 
bacteria using the plasmid constructs described in 
earlier publications [68, 74-76]. The protocol for the 
expression of POR variants and membrane as well 
as liposome preparation is reported in our earlier 
publications [64-66, 68, 74, 77].  
 
CYP19A1 activity measurement in the 
reconstituted liposome system. CYP19A1 activity 
of proteins was monitored by the tritiated water 
release assay based on an earlier method described 
by Lephart and Simpson [78] with slight 
modifications that have been described previously 
using an assay system containing lipids, POR and 
CYP19A1 [64, 68].  Androstenedione was used as 
the substrate for the CYP19A1 reaction. POR and 
CYP19A1 proteins were mixed into liposomes 
containing 1,2-Dilauroyl-sn-glycero-3-
phosphorylcholine (DLPC) and 1,2-Dilauroyl-sn-
glycero-3-phosphorylglycerol (DLPG).  Reaction 
mixture consisted of 50 pmol of CYP19A1, 200 
pmol of POR and 20,000 cpm of 3H 
androstenedione ([1ᵝ-3H(N)]-andros-tene-3,17-
dione;) in 100 mM potassium phosphate buffer (pH 
7.4) with 100 mM NaCl. Different concentrations 
of androstenedione (0.01–30 µM) were used for 
assays to study the enzyme kinetics. The enzymatic 
reaction of CYP19A1 was started by adding 
NADPH to 1 mM concentration, and reaction 
mixtures were incubated with shaking for 1 h. The 
reaction was stopped by adding chloroform and the 
water phase was mixed with a 5% charcoal/0.5% 
dextran solution and centrifuged at 14000 x g for 5 
minutes and 0.5 ml of supernatant was used for 3H 
radioactivity counting. The specific activity of 
human CYP19A1 was calculated as (pmol of 
product/minute of incubation/nmol of P450), where 
pmol of the product formations were calculated as: 
 
[cpmsample – cpmblank] ∙ pmol of cold 
androstenedione/total cpm 
 
Data were analyzed using GraphPad Prism 
(GraphPad, La Jolla, CA) based on Michaelis-
Menten kinetics to determine the Vmax and Km. 
Values obtained from triplicate experiments were 
expressed as mean ± S.E.M. (standard error of 
mean). 
 
FASTpp assay of CYP19A1 and its polymorphic 
variants R264H and R264C: The FASTpp assay 
was performed as described previously [66, 79, 80]. 
Reaction mixtures contained 0.2 mg/mL of 
CYP19A1 WT or polymorphic variants R264H and 
R264C, 10 mM CaCl2, 0.05 mg/mL thermolysin in 
0.1 M potassium phosphate buffer (pH 7.4) 
containing 20% glycerol, 0.1 % Tween-20, and 1 
mM β-mercaptoethanol. A negative control reaction 
was carried out without including thermolysin. 




a TGradient Thermoblock (Biometra, Switzerland), 
generating a temperature gradient from 30 to 70°C, 
and reactions were stopped by addition of 10 mM 
EDTA (pH 8.0). Samples were analyzed by SDS-




Figure 2: Location of CYP19A1 and POR variants: A. Locations of CYP19A1 variants in protein structure. The R264 residue 
on CYP19A1 is surface exposed and located on the G helix of the CYP19A1 structure, which is part of the substrate access 
channel, and it has been widely reported to be flexible in cytochromes P450. Here a ribbons model of CYP19A1 protein is shown, 
and the bound substrate, androstenedione, is depicted as sticks model. B. Locations of POR variants. X-ray crystal structure of 
the human POR (PDB#3QE2) depicting the positions of POR variations described in this study. The co-factors FAD, FMN, and 
NADP are depicted as sticks. The P284 residue is situated in the hinge region of the POR. The hinge region of POR is vital for 
flexibility and conformation shifts in POR, and mutations in this region of POR may create changes in conformation that would 
modify the interactions of POR with its partner proteins. The Y607 residue is located in the NADPH binding site of POR. Binding 
of NADPH is required for the transfer of electrons to redox partners of POR as well as direct reduction of dyes and small 




Population Genetics of CYP19A1 amino acid 
variants R264C and R264H 
 
The R264C variant of CYP19A1 is present at a low 
frequency in the European population with a minor 
allele frequency (MAF) of 0.02 in the 1000 Genomes 
database (Table 1). Among the American population, 
the MAF of R264C was 0.04. In the East Asian (MAF 
0.17), South East Asian (MAF 0.24), and African 
(MAF 0.18) populations, the R264C variant was 
present at a much higher frequency. Looking 
individually, the Italian population from Tuscany had 
the lowest occurrence of R264C with a MAF of 0.006 
in the HapMap database (Table 1). In the HapMap 
database, the R264C variant was found in a Mexican 
population with a MAF of 0.01, while the Japanese 
population showed the highest presence of R264C with 
a MAF of 0.27. HapMap data showed similar MAF 
among subpopulations as reported in 1000 Genome 
database, the only exception being the Maasai 
population from Kenya, which had the R264C allele 
present at the MAF of 0.04, which is much lower than 
the distribution seen in other African populations. On 
the other hand, the R264H variant of CYP19A1 
(rs2304462) is found only as a rare variant present at a 
MAF of 0.00003 in ExAc Aggregated Populations and 





Table 1: Genetic data for the CYP19A1 variations. The R264C (DBSNP: rs700519 ) is a common polymorphism in the CYP19A1 
gene. Population codes referred to in the table are for 1000 Genome: AMR American; AFR African; EAS East Asian; SAS South 
East Asian; EUR European. For the HapMap project: ASW, African ancestry in Southwest USA; CEU, Utah residents with 
Northern and Western European ancestry; CHB, Han Chinese in Beijing, China; CHD, Chinese in Metropolitan Denver, 
Colorado; GIH, Gujarati Indians in Houston, Texas; JPT, Japanese in Tokyo, Japan; LWK, Luhya in Webuye, Kenya; MEX, 
Mexican ancestry in Los Angeles, California, USA; MKK, Maasai in Kinyawa, Kenya; TSI, Toscans in Italy; YRI, Yoruba in 
Ibadan, Nigeria. The R264H (rs2304462) is a rare variant and has been seen with lower frequencies across populations. Data for 
population genetic distribution of variants were retrieved from the NCBI (http://www.ncbi.nlm.nih.gov). Populations with a minor 
allele frequency that is significantly higher than average are shown in bold. 
 
Population ID-Class Number of 
alleles 
Major Allele Freq. Minor Allele Freq. 
R264C (rs700519 )    
1000 Genome 5008 G=0.860 A=0.140 
1000 Genome- AMR 694 G=0.96109998 A=0.03890000 
1000 Genome-AFR 1322 G=0.81770003 A=0.18230000 
1000 Genome-EAS 1008 G=0.82940000 A=0.17060000 
1000 Genome-SAS  978 G=0.76279998 A=0.23720001 
1000 Genome-EUR 1006 G=0.97119999 A=0.02880000 
    
ESP-cohort North America 4542 G=0.91391456 A=0.08608542 
    
HapMap    
HapMap-CEU 224 G=0.96875000 A=0.03125000 
HapMap -TSI 174 G=0.99425286 A=0.00574713 
HapMap -MEX 98 G=0.98979592 A=0.01020408 
HapMap -CHD 170 G=0.88235295 A=0.11764706 
HapMap -JPT 172 G=0.72674417 A=0.27325583 
HapMap -ASW 98 G=0.83673471 A=0.16326530 
HapMap -GIH 174 G=0.83908045 A=0.16091955 
HapMap -CHB 82 G=0.85365856 A=0.14634146 
HapMap -YRI 224 G=0.78571427 A=0.21428572 
HapMap -LWK 180 G=0.88888890 A=0.11111111 
HapMap -MKK 286 G=0.95804197 A=0.04195804 
    
R264H (rs2304462)    
ExAc Aggregated 
Populations 
121366 C=0.99996704 T=0.00003296 
gnomAD-Exomes 246062 C=0.99998 T=0.00002 
 
Genetics of variants in POR 
 
The POR variants described in this study were 
selected by searching the genetic sequence 
databases. Selected variants were subjected to 
stability analysis on protein structure followed by 
sequence conservation studies to filter the variants 
with disease-causing possibilities [59]. Human POR 
protein has 680 amino acids and has evolved from 
the ferredoxin reductase and ferredoxin like 
structures to create a single P450 reductase protein 
in higher eukaryotes [81].  The POR variations 
described here are highly conserved among 
different species and are described as rare genetic 
variants in the Exome database of NCBI (Table 2). 
The P284L is a rare variant found mostly in 
Europeans, and the P284T variant had been only 
observed in an African population [64, 82, 83]. The 
Y607C is a rare genetic variant found in both the 
Asian and European populations (Table 2). 
 
Structure analysis of variants in CYP19A1 and 
POR  
 
The R264 residue on CYP19A1 is surface exposed 
and located on the G helix of the CYP19A1 structure 
(Figure 2A), which is part of the substrate access 
channel, and it has been widely reported to be flexible 
in cytochromes P450. R264 is the central residue of a 




sequence for multiple kinases. Thus, it can play a 
central role in both the formation of substrate access 
and CYP19A1 activity by post-translational 
modifications (51). The amino acid P284 is situated 
in the flexible hinge region, between the FAD and 
FMN binding domains of POR (Figure 2B). This 
hinge region is responsible for flexibility and domain 
movements in POR. Mutations in the POR that are 
located in the hinge region may cause conformational 
changes that would change the interactions between 
POR and its protein/small molecule partners [42, 64]. 
The Y607 residue is located close to the NADPH 
binding site (Figure 2B), and the Y607C variant in 
POR has been shown to reduce the CYP19A1 
catalytic efficiency by 90% [65]. 
 
 
Table 2: Minor allele Frequencies of variants in POR described in this study according to the Exome database of NCBI. 
 
POR DBSNP id 
 
Global European Asian American African 
       
P284L rs72557938 T=0.00005 T=0.00004 T=0.0001 T=0.0000 T=0.0000 
P284T rs72557937 A=0.00004 A=0.00000 A=0.0000 A=0.0000 A=0.0005 
Y607C rs72557954 G=0.00011 G=0.00008 G=0.0003 G=0.0000 G=0.0000 
 
 
Figure 3: Aromatase activity of CYP19A1 variants with 
WT-POR. CYP19A1 wild type (solid line) and mutants 
CYP19A1R264H (dashed line) and CYP19A1R264C (dashed-
dotted line) activities supported by POR-WT were tested to 
compare the activities of three different types of CYP19A1 
variants. Recombinant preparations of purified human 
CYP19A1 (WT and variants) expressed in bacteria and 
recombinant human POR were combined into liposomes. 
CYP19A1 activity to biotransform androstenedione (3H 
labeled) to estrone was measured by monitoring the release 
of tritiated water. Data are shown as mean ± SEM of three 
independent replicates. Data were fitted using GraphPad 
Prism, according to the Michaelis-Menten kinetics model. 
The Km and Vmax values calculated from these assays and 
statistical analysis are given in Table 3. 
 
Enzyme activity of CYP19A1 and its 
polymorphic variants R264H and R264C 
supported by POR-WT 
 
We performed in-vitro CYP19A1 activity assays 
with the WT CYP19A1 and its polymorphic 
variants (R264H and R264C) to study the effects 
of the two variations on the enzyme activity. To 
this aim, reconstituted liposomes were prepared 
by mixing the purified recombinant CYP19A1 
with purified membranes containing WT-POR as 
described in materials and methods. Then we 
assessed the enzyme activity by standard tritiated 
water release assay. For the R264H variant of 
CYP19A1, the apparent Km for androstenedione 
was comparable to that of WT CYP19A1, 
whereas the apparent Vmax was reduced by ~30% 
(Figure 3, Table 3). The catalytic efficiency of the 
CYP19A1-R264H variant was reduced by ~13% 
compared to WT CYP19A1. However, for the 
R264C variant of CYP19A1, the apparent Km for 
androstenedione increased by 3.2 fold as 
compared to WT CYP19A1. The apparent Vmax 
was reduced by ~50%.  
 
Therefore, the CYP19A1-R264C variant showed 
a seven-fold reduction in catalytic efficiency 
(Vmax/Km) with only 15% of the residual 
CYP19A1 activity as compared to WT CYP19A1 




efficiency indicates that R264C mutation of 
CYP19A1 affects either the interaction of the 
substrate with CYP19A1 or the CYP19A1-POR 
interaction, which may influence electron transfer 
from POR to CYP19A1 for metabolic reactions.
 
Table 3. Kinetic parameters for activities of CYP19A1 and its polymorphic variants supported by WT POR. Variable 
androstenedione concentration (0.3–30 µM) were used for the biotransformation of androstenedione into estrone. All assays were 
performed with 1 mM NADPH. Data are shown as mean ± SEM of independent replicates (n=3). Catalytic efficiencies of 
different combinations of POR and CYP19A1 variants are given as a percentage of WT-POR and WT-CYP19A1 combination 












CYP19A1 (aromatase) activity for the Conversion of androstenedione to estrone 
CYP19A1-WT 1.6 ± 0.9 35.5 ± 4.7 21.6 100.0 
CYP19A1-R264H 1.3 ± 0.9 25.2 ± 4.1 18.8 87.0 
CYP19A1-R264C 5.1 ± 2.6 16.9 ± 2.8* 3.3* 15.3* 
 
Table 4. Kinetic values for the activities of CYP19A1 and its polymorphic variants supported by variant forms of POR. For the 
conversion of androstenedione to estrone, variable amounts (0.3–30 µM) of androstenedione were used for enzyme assays, and 
the NADPH was fixed at 1mM. Data are shown as mean ± SEM of three independent replicates. Catalytic efficiencies of different 
combinations of POR and CYP19A1 variants are given as a percentage of WT-POR and WT-CYP19A1 combination (% of WT-
WT catalytic efficiency). * represents statistically significant differences from the POR-WT control (*p<0.05 based on two 












POR-P284L     
CYP19A1-WT 99.7 ± 312.0 37.4 ± 92.7 0.4 1.7 
CYP19A1-R264H 55.2 ± 49.7 38.6 ± 24.0 0.7 3.2 
CYP19A1-R264C n.d. n.d. n.d. n.d. 
POR-P284T     
CYP19A1-WT 22.5 ± 36.2 15.8 ± 13.2 0.7 3.3 
CYP19A1-R264H 51.0 ± 56.5 24.5 ± 18.7 0.5 2.2 
CYP19A1-R264C 19.9 ± 31.7 28.7 ± 22.0 1.4 6.7 
POR-Y607C     
CYP19A1-WT 4.7 ± 2.5 18.3 ± 3.0* 3.9* 18.2* 
CYP19A1-R264H 1.3 ± 0.6 17.7 ± 1.7* 13.6 63.1 
CYP19A1-R264C 77.5 ± 133.6 81.1 ± 105.0 1.0 4.8 
Stability analysis of CYP19A1 and its 
polymorphic variants R264H and R264C by Fast 
Proteolysis Assay (FASTpp) 
 
To compare the biophysical protein stability of 
CYP19A1 and its polymorphic variants R264H and 
R264C, we used a FASTpp assay with the 
recombinantly expressed and purified CYP19A1 
proteins. CYP19A1-WT and variants were exposed 
in parallel to a range of different temperatures with 
the thermostable protease Thermolysin. 
Thermolysin readily cleaves the unfolded proteins 
near the hydrophobic residues Phe, Leu, Ile, and Val 




protein. Increasing the reaction temperature induces 
the thermal unfolding of proteins and the 
temperature-dependent changes in the degradation 
pattern represent the readout for the thermal stability 
of proteins. The SDS-PAGE analysis of the parallel 
FASTpp of CYP19A1-WT and variants (Figure 4A 
and B) showed that the R264H and R264C 
mutations do not display any major changes in 
protein stability. Therefore, it seems likely that the 
conformational changes induced by R264C and 
R264H variations do not significantly alter the 
structural stability of CYP19A1. However, the 
structural changes caused by R264C and R264H 
variations may alter the delicate balance of protein-
protein interactions that are needed for the transfer 




Figure 4: FastPP assay for the stability of CYP19A1 
variants. Protein stability analysis of aromatase mutants 
CYP19A1R264H (dashed line) and CYP19A1R264C (dashed-
dotted line) compared to CYP19A1-WT (solid line) by 
FASTpp assay. Thermolysin (0.05) mg/mL) was used to digest 
0.20 mg/mL of CYP19A1-WT or mutants at increasing 
temperatures ranging from 4°C to 70°C. NoE represents the 
negative control carried out without thermolysin. The 
experiments were repeated three times, and here, a 
representative SDS-PAGE is shown. Each data-set represents 
mean ± SEM of three experiments. Data were analysed by 
Dunnett's multiple comparisons test and the differences were 
not found to be statistically significant between the groups, 
indicating all variants have similar stability as the WT-
CYP19A1. 
 
Variable effects on the enzyme activity of 
CYP19A1 and its polymorphic variants R264H 
and R264C are shown by POR variants 
To study how different variants of CYP19A1 
interact with variants of POR, we tested three 
polymorphic variants of POR (P284L, P284T, and 
Y607C) in supporting CYP19A1 enzyme activity. 
We tested the in-vitro estrogen synthase activity of 
CYP19A1 by the tritiated water release assay with 
the reconstituted liposomes using androstenedione 
as a substrate. The POR variants P284L and P284T 
showed a severe loss of enzyme activity with all 
CYP19A1 variants tested (Figure 5A-B, Table 4). 
For the POR variant P284L, the Km (apparent) for 
androstenedione was elevated ~60 fold and ~35 fold 
as compared to WT POR with CYP19A1 and 
CYP19A1-R264H. The apparent Vmax of POR-
P284L was comparable to that of POR-WT in 
supporting CYP19A1 and CYP19A1-R264H 
activity. However, the product of enzymatic 
reaction with POR-P284L and CYP19A1-R264C 
was undetectable, and therefore, Km and Vmax 
could not be determined. For the POR-P284T, the 
Km (apparent) for androstenedione was elevated by 
~14, ~32, and ~12 fold with the CYP19A1-WT, 
CYP19A1-R264H, and CYP19A1-R264C 
respectively. The apparent Vmax was reduced by 
~55%, ~30%, and ~20% with the CYP19A1-WT, 
CYP19A1-R264H, and CYP19A1-R264C, 
respectively.  
 
POR-Y607C variant supports CYP19A1-R264H 
better than WT CYP19A1. 
 
For the POR variant Y607C, the Km (apparent) for 
androstenedione was elevated by ~3 and ~48 fold 
with the CYP19A1-WT and CYP19A1-R264C 
respectively (Figure 5C, Table 4). The apparent 
Vmax was reduced by ~50%, with both CYP19A1-
WT and CYP19A1-R264H.  The residual catalytic 
efficiency of CYP19A1-WT, CYP19A1-R264H, 




18.2%, 63.1 and 4.8% respectively as compared to 
POR-WT: CYP19A1-WT activity. Interestingly, the 
POR-Y607C variant supports the reaction of 




POR is the obligate electron donor for all P450 
enzymes in the endoplasmic reticulum and supplies 
electrons for the catalytic activities of CYP19A1 
[42, 68, 84]. The CYP19A1 deficiency is linked to 
genetic disorders of estrogen biosynthesis in women 
and developmental disorders in men [19, 31, 46, 85, 
86]. Previously we have tested the CYP19A1 
variants (R264C and R26H) and POR genetic 
variants in separate studies that focused on 
individual genes [59, 64, 70]. Cytochromes P450 
and P450 reductase have a large number of genetic 
variations and, therefore, many individuals may 
harbor variations in P450 reductase as well as P450 
genes that may alter the enzymatic activities of 
cytochromes P450 [87]. So far, combined effects of 
variations in P450 reductase and steroidogenic P450 
have not been tested, despite many reports on effects 
of genetic variations that were tested separately, 
using the WT P450 proteins with variant forms of 
POR; or P450 variants tested with WT-POR. There 
is only one report in literature describing the effects 
of genetic variations in a P450 protein (CYP2C9) 
with some POR variations [63].  
 
In this report, we have tested the combinations of 
genetic variants in CYP19A1, responsible for 
estrogen production, with variant forms of POR. 
The R264C is a common polymorphism in 
CYP19A1 with a higher frequency in Asian and 
African populations compared to American, 
Mexican, or European populations. The only 
exception was found in the Maasai population from 
Kinyawa in Kenya, where the R264C variant of the 
CYP19A1 was present at a frequency similar to that 
of European or American populations (Table 1).  
The prevalence of the R264C variant of the 
CYP19A1 is high in Japanese, Chines, and southeast 
Asian populations. Among the POR variants 
studied, The Y607C has also been observed in the 
southeast Asian population [59]. In the CYP19A1 
activity assays using bacterially expressed 
recombinant forms of POR and CYP19A1 proteins, 
we studied the combined effects of POR and 
CYP19A1 variants in different permutations and 
combinations of the two proteins. First, we tested 
the variant forms of CYP19A1 with WT POR and 
found that the CYP19A1-R264C variant lost around 
85% of CYP19A1 catalytic efficiency, while the 
catalytic efficiency of CYP19A1-R264H variant 
was decreased by 14% when compared to WT-
CYP19A1. These data are similar to the previous 
reports, where the two CYP19A1 polymorphic 
variants showed a decrease in the catalytic 
efficiency compared to the WT protein [51]. 
However, in this work, the amount of the activity 
loss was different, and this can be explained with a 
different experimental setup due to the 
incorporation of the enzymes in liposomes, the use 
of higher amounts of POR (4:1 versus 1:1 ratio) and 




Figure 5: Enzyme assay of CYP19A1 variants . WT-
CYP19A1(solid line), R264H-CYP19A1 (dashed line) and 




POR-P284L, B: POR-P284T, C: POR-Y607C. CYP19A1 
activity supported by the wild type POR is shown in all three 
graphs as a reference (dash-dotted line). Human CYP19A1 
(WT and variants R264C/R264H) and human POR (WT and 
variants P284L/P284T/Y607C) were embedded into 
liposomes, and aromatization activity to convert 
androstenedione into estrone was monitored by the release of  
3H water during the reaction. Data are shown as mean ± SEM 
of three independent replicates. Data were fitted with 
GraphPad Prism using the kinetics model described by 
Michaelis and Menten. The Km and Vmax values calculated 
from these experiments and statistical analysis are shown in 
Table 3 and Table 4. 
 
POR is a membrane-bound protein that uses 
NADPH as a substrate for electron transfer. The 
binding of NADPH results in a conformational 
change that brings NAHPH close to the bound FAD 
in POR for the transfer of electrons. Afterward, 
additional changes in conformation cause a 
tightening of the POR structure, which brings the 
FAD closer to the FMN for the transfer of electrons 
from FAD to FMN. The P450 redox partners of 
POR interact with the FMN binding domain through 
ionic interactions involving lysine and arginine 
residues on the surface of P450s and the glutamate 
and aspartate residues located on the surface of POR 
[88-91]. Considering the importance of the hinge 
region of POR in both the intermolecular electron 
transfer as well as interactions with partner proteins, 
we studied the effects of variations in the hinge 
region of POR on the enzymatic activities of 
CYP19A1 variants. The main reason behind such 
sensitivity of CYP19A1 towards changes in POR 
may be due to its requirement of six pairs of 
electrons to complete the conversion of androgens 
(androstenedione, testosterone) to estrogens 
(estrone, estradiol). By this logic, it is possible that 
changes in the conformation of POR that affect 
interactions with CYP19A1, could, in turn, affect 
CYP19A1 activities. The P284L (rs 72557938) and 
P284T (rs72557937) variants are situated in the 
flexible hinge region of POR, which is important for 
movements of different domains, including the 
interactions between FMN and FAD-binding 
domains for the transfer of electrons from FAD to 
FMN (Figure 2B). In a study by Miller laboratory 
which analyzed genetic variations of POR in 
different populations, the POR variant P284L was 
found with an allele frequency of 0.003 in the 
Chinese Americans [76], and in the ExAc dataset 
from NCBI, the P284L variant of POR has an allele 
frequency of 0.00004. Huang et al. have reported a 
54% loss of CYP17A1 17α-hydroxylase activity 
with POR P284L but found the 17,20 lyase activity 
of CYP17A1 to be similar to the wild type POR 
[76]. Recently we have shown that the P284L and 
P284T variants of POR showed reduced enzymatic 
activities with several drug-metabolizing 
cytochromes P450 [83, 87]. There was a 55% loss 
of activity in CYP2C19 and CYP3A5 assays, while 
a 78% loss of activity was observed in CYP2C9 
assays with the P284L variant of POR compared to 
the WT protein [87]. Flavin content was not affected 
by the variation P284L in POR [64], indicating a 
change in protein-protein interactions, both the inter 
as well as intramolecular; may be behind the 
reduced CYP19A1 activities. In case of P284T 
variant of POR a reduction of both the FAD as well 
as FMN content has been observed [83]. The drug 
metabolizing cytochrome P450 enzyme activities 
were also reduced when the POR-P284T was used 
as a redox partner (CYP2C9, 26%; CYP2C19, 44%; 
CYP3A4, 23% and CYP3A5, 44% of WT POR) 
[83]. Because the flexible hinge region of POR is 
necessary for the movement of domains that brings 
the FAD closer to the FMN for the transfer of 
electrons, a change in the hinge region may alter the 
electron transfer process in POR, affecting the 
activities of redox partners [92]. It is likely that 
some electron transfer partners of POR may show a 
more significant effects on their enzymatic 
activities, while other redox partners of POR might 
remain unaffected depending on the precise nature 
of their interactions with the POR [93].  
As seen with the P284L, P284T, and the 
Y607C mutations, there may be variations of POR 
in the seemingly non-clinical populations that show 
adverse effects on the enzymatic activities of 
multiple cytochrome P450 enzymes. Since 
variations in POR are now linked to the changes in 
the metabolism of many drugs, steroids, and small 
molecule substrates, variations in the POR gene 
should be considered as a candidate for genetic 
defects causing abnormal steroid or drug 
metabolism [59, 60, 62, 64, 75]. Further studies on 
genetic variants of POR shall be conducted to check 
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